Allogene Therapeutics, Inc. (ALLO)

Market Cap	365.00M
Revenue (ttm)	22,000
Net Income (ttm)	-257.59M
Shares Out	217.26M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,052,229
Open	1.530
Previous Close	1.540
Day's Range	1.510 - 1.700
52-Week Range	1.230 - 3.780
Beta	0.99
Analysts	Strong Buy
Price Target	9.66 (+475.0%)
Earnings Date	May 12, 2025

About ALLO

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that ta...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 11, 2018
• Employees: 229
• Stock Exchange: NASDAQ
• Ticker Symbol: ALLO
• Website: https://allogene.com

Financial Performance

In 2024, Allogene Therapeutics's revenue was $22,000, a decrease of -76.84% compared to the previous year's $95,000. Losses were -$257.59 million, -21.29% less than in 2023.

Analyst Forecast

According to 10 analysts, the average rating for ALLO stock is "Strong Buy." The 12-month stock price forecast is $9.66, which is an increase of 475.00% from the latest price.

Price Target

$9.66

(475.00% upside)

Analyst Consensus: Strong Buy